Verification of the Efficacy of NPC-15 for Sleep Disorders of Children With Autism Spectrum Disorders (NPC-15-5)

Nobelpharma Co., Ltd. logo

Nobelpharma Co., Ltd.

Status and phase

Completed
Phase 3
Phase 2

Conditions

Sleep Disorders
Autism Spectrum Disorder

Treatments

Drug: NPC-15 Granules Lower Dose
Drug: NPC-15 Placebo Granule
Drug: NPC-15 Granules Higher Dose

Study type

Interventional

Funder types

Industry

Identifiers

NCT02757066
NPC-15-5

Details and patient eligibility

About

The purpose of this study is to verify the efficacy of NPC-15 (melatonin 1 mg/d or 4 mg/d) versus placebo to sleep latency with electronic sleep diaries.

Full description

This study will be a multicenter, double-blind, randomized, placebo-controlled parallel group trial. The trial has five phases; the pre-screening phase, the screening phase, double-blinded treatment phase, open label treatment phase and post-treatment phase. The screening phase comprises a screening visit where subject's initial eligibility will be evaluated. During double-blinded treatment phase, patients who meet all entry criteria for the trial will be randomized into three groups, and they will be assigned NPC-15 1 mg, 4 mg or placebo before going to bed for 2 weeks. During open label treatment phase, all patients will be administered NPC-15 1 mg, 2 mg or 4 mg on the basis of their doctors' judgements.

Enrollment

196 patients

Sex

All

Ages

6 to 15 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Female or male patients aged 6 to 15 years.
  • Patients with "autism spectrum disorder" diagnosed by using DSM-5.
  • Patients with average of daily sleep latency persisted over 30 min and the condition is continuous over 3 months
  • Patients who are out-patient, not hospitalized patient.
  • Signed informed consent obtained from rearer(s)/parent(s)/guardian(s) of the patient, or signed IC or informed assent obtained from the patient themselves.

Exclusion criteria

  • Patients with at least severity in either Conceptual area, or Social area, or Practical area of intellectual disability have judged more than "severe" by using DSM-5.
  • Patients who took melatonin (including supplement) in history.
  • Patients who had taken Ramelteon within 4 weeks before clinical study starts.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Quadruple Blind

196 participants in 3 patient groups, including a placebo group

NPC-15 Granules Lower Dose
Experimental group
Description:
NPC-15 Granules Lower Dose group which is administered 1mg melatonin
Treatment:
Drug: NPC-15 Granules Lower Dose
NPC-15 Granules Higher Dose
Experimental group
Description:
NPC-15 Granules Higher Dose group which is administered 4 mg melatonin
Treatment:
Drug: NPC-15 Granules Higher Dose
NPC-15 Placebo Granule
Placebo Comparator group
Description:
NPC-15 Placebo Granules group which is administered placebo melatonin
Treatment:
Drug: NPC-15 Placebo Granule

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems